Table 2.
Univariate analysis of different variables on OS and DFS
| Clinical/Pathologic factor | No. | 5-y OS % | P | 5-y DFS % | P |
|---|---|---|---|---|---|
| All | 269 | 53.2 | 44.6 | ||
| Gender | 0.470 | 0.239 | |||
| Male | 189 | 51.9 | 40.7 | ||
| Female | 80 | 56.3 | 53.8 | ||
| Age (years) | 0.056 | 0.090 | |||
| <60 | 195 | 48.7 | 41.5 | ||
| >60 | 74 | 64.9 | 52.7 | ||
| Tumor location (cm) | 0.792 | 0.777 | |||
| <5 | 162 | 51.9 | 43.2 | ||
| 5-10 | 102 | 55.9 | 47.1 | ||
| >10 | 5 | 40.0 | 40.0 | ||
| Differentiation | 0.178 | 0.154 | |||
| Well-differentiated | 11 | 72.7 | 63.6 | ||
| Moderately-differentiated | 223 | 53.4 | 45.7 | ||
| Poorly-differentiated | 35 | 45.7 | 31.4 | ||
| Histological typing | 0.914 | 0.657 | |||
| Adenocarcinoma | 229 | 54.1 | 45.4 | ||
| Mucinous adenocarcinoma | 31 | 48.4 | 41.9 | ||
| Signet ring cell carcinoma | 9 | 44.4 | 33.3 | ||
| Chemotherapy regimens | 0.455 | 0.583 | |||
| Single-capecitabine/5-Fu | 23 | 43.4 | 43.5 | ||
| XELOX/FOLFOX | 246 | 54.1 | 44.7 | ||
| Pre-NACRT CEA (ng/mL) | 0.060 | 0.060 | |||
| <5*10-6 | 129 | 58.1 | 50.4 | ||
| >5*10-6 | 140 | 48.6 | 39.3 | ||
| Post-NACRT CEA (ng/mL) | <0.001 | <0.001 | |||
| <5*10-6 | 234 | 57.3 | 47.4 | ||
| >5*10-6 | 35 | 25.7 | 25.7 | ||
| Clinical T stage | 0.176 | 0.168 | |||
| T2 | 2 | 0 | 0 | ||
| T3 | 101 | 55.4 | 49.5 | ||
| T4 | 166 | 52.4 | 42.2 | ||
| Clinical N stage | 0.213 | 0.120 | |||
| N0 | 115 | 58.3 | 48.7 | ||
| N+ | 154 | 49.4 | 41.6 | ||
| Pathologic T stage | <0.001 | <0.001 | |||
| T0 | 61 | 78.7 | 68.9 | ||
| T1 | 3 | 66.7 | 33.3 | ||
| T2 | 46 | 76.1 | 71.7 | ||
| T3 | 120 | 40.0 | 29.2 | ||
| T4 | 39 | 25.6 | 23.1 | ||
| Pathologic N stage | <0.001 | <0.001 | |||
| N0 | 173 | 64.2 | 55.5 | ||
| N1 | 62 | 35.5 | 25.8 | ||
| N2 | 34 | 29.4 | 23.5 | ||
| AJCC-TRG | <0.001 | <0.001 | |||
| TRG0 | 67 | 74.6 | 64.2 | ||
| TRG1 | 78 | 55.1 | 47.4 | ||
| TRG2 | 78 | 47.4 | 37.2 | ||
| TRG3 | 46 | 28.3 | 23.9 |
Abbreviation: TRG, Tumor regression grade; NACRT, Neoadjuvant chemoradiotherapy; CEA, Carcinoembryonic antigen; OS, Overall survival; DFS, Disease-free survival.